"2"^^ . "Malignant melanoma"@en . "Malign\u00ED melanom"@cs . "Melanom k\u016F\u017Ee vznik\u00E1 malign\u00ED transformac\u00ED ko\u017En\u00EDch melanocyt\u016F. \u0158ad\u00ED se mezi nejmalign\u011Bj\u0161\u00ED n\u00E1dory d\u00EDky tendenci k \u010Dasn\u00E9mu lymfogenn\u00EDmu a hematogenn\u00EDmu metastazov\u00E1n\u00ED. Pr\u016Fm\u011Brn\u00FD v\u011Bk pacienta s melanomem je pom\u011Brn\u011B n\u00EDzk\u00FD- 54 let a \u010Dtvrtina pacient\u016F je mlad\u0161\u00EDch 40 let. Incidence melanomu roste konstantn\u011B o 4 % ro\u010Dn\u011B. Progn\u00F3za pacienta je z\u00E1visl\u00E1 na tlou\u0161\u0165ce n\u00E1doru, a proto je v\u010Dasn\u00E1 diagnostika esenci\u00E1ln\u00ED pro p\u0159\u00EDzniv\u00FD v\u00FDvoj onemocn\u011Bn\u00ED. Zp\u0159esn\u011Bn\u00ED diagnostiky p\u0159inesla dermatoskopie, zejm\u00E9na jej\u00ED digit\u00E1ln\u00ED podoba. Zku\u0161en\u00E9mu dermatologovi pom\u016F\u017Ee zp\u0159esnit diagnostiku pigmentov\u00FDch projev\u016F ze 70 % na 95 %. Mortalita na melanom z\u016Fst\u00E1v\u00E1 od 80. let minul\u00E9ho stolet\u00ED konstantn\u00ED i p\u0159es neust\u00E1l\u00FD v\u00FDvoj nov\u00FDch medikament\u016F sm\u011B\u0159uj\u00EDc\u00EDch k prodlou\u017Een\u00ED celkov\u00E9ho p\u0159e\u017Eit\u00ED pacient\u016F." . "Malignant melanoma"@en . . "[0F7F73D3F598]" . "Malign\u00ED melanom" . "Refer\u00E1tov\u00FD v\u00FDb\u011Br z onkologie" . . "Melanom k\u016F\u017Ee vznik\u00E1 malign\u00ED transformac\u00ED ko\u017En\u00EDch melanocyt\u016F. \u0158ad\u00ED se mezi nejmalign\u011Bj\u0161\u00ED n\u00E1dory d\u00EDky tendenci k \u010Dasn\u00E9mu lymfogenn\u00EDmu a hematogenn\u00EDmu metastazov\u00E1n\u00ED. Pr\u016Fm\u011Brn\u00FD v\u011Bk pacienta s melanomem je pom\u011Brn\u011B n\u00EDzk\u00FD- 54 let a \u010Dtvrtina pacient\u016F je mlad\u0161\u00EDch 40 let. Incidence melanomu roste konstantn\u011B o 4 % ro\u010Dn\u011B. Progn\u00F3za pacienta je z\u00E1visl\u00E1 na tlou\u0161\u0165ce n\u00E1doru, a proto je v\u010Dasn\u00E1 diagnostika esenci\u00E1ln\u00ED pro p\u0159\u00EDzniv\u00FD v\u00FDvoj onemocn\u011Bn\u00ED. Zp\u0159esn\u011Bn\u00ED diagnostiky p\u0159inesla dermatoskopie, zejm\u00E9na jej\u00ED digit\u00E1ln\u00ED podoba. Zku\u0161en\u00E9mu dermatologovi pom\u016F\u017Ee zp\u0159esnit diagnostiku pigmentov\u00FDch projev\u016F ze 70 % na 95 %. Mortalita na melanom z\u016Fst\u00E1v\u00E1 od 80. let minul\u00E9ho stolet\u00ED konstantn\u00ED i p\u0159es neust\u00E1l\u00FD v\u00FDvoj nov\u00FDch medikament\u016F sm\u011B\u0159uj\u00EDc\u00EDch k prodlou\u017Een\u00ED celkov\u00E9ho p\u0159e\u017Eit\u00ED pacient\u016F."@cs . . . . . . "0034-2815" . . . . "Malign\u00ED melanom"@cs . "1-2" . "Cutaneous malignant melanoma originates from neoplastic proliferation of melanocytes. Due to its early lymphogenic and haematogenic metastazing, melanoma belongs to the most malignant tumours. The disease occurs quite early; one quarter of patients with melanoma is younger than 40 years and the mean age of a melanoma patient is 54 years. The incidence of this tumour is growing constantly, about 4% per year. The patient's prognosis depends on the tumour thickness and the early diagnostics is therefore essential for the favourable disease outcome. The accuracy of the melanoma clinical diagnostics has been enhanced by introduction of dermoscopy, particularly by its digital form. For the trained dermatologist it improves the accuracy of the clinical decision from usual 70 to more than 95%. The malignant melanoma mortality rate remains constant since the eighties of the 20th century. Exploration of new substances which should be able to prolong the patient's survival in metastatic stage is therefore in progress."@en . "Vedral, Tom\u00E1\u0161" . "RIV/00064173:_____/09:00002091!RIV13-MZ0-00064173" . . . . "P(1A8243), V" . "CZ - \u010Cesk\u00E1 republika" . "Malign\u00ED melanom" . . "324479" . "Arenbergerov\u00E1, Monika" . . "9"^^ . . "mortality; therapy; dermoscopy; incidence; melanocyte; malignant melanoma"@en . . "26" . "2"^^ . "RIV/00064173:_____/09:00002091" . . . .